Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

New drugs and new trials in melanoma

Prof Jean-Jacques Grob - Marseille University, Marseille, France

New drugs and new trials in melanoma ( Prof Jean-Jacques Grob - Marseille University, Marseille, France )

Disruptive technologies in cancer

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Disruptive technologies in cancer ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Anti-PD-1 or anti-CTLA-4 in first line therapy?

Prof Claus Garbe - University of Tübingen, Tübingen, Germany

Anti-PD-1 or anti-CTLA-4 in first line therapy? ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany )

Long response and long responders in melanoma immunology

Prof Georgina Long - University of Sydney, Sydney, Australia

Long response and long responders in melanoma immunology ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Benefit and risk analysis from the phase III OPTiM trial

Dr Kevin Harrington - Institute of Cancer Research, London, UK

Benefit and risk analysis from the phase III OPTiM trial ( Dr Kevin Harrington - Institute of Cancer Research, London, UK )

Progress in targeted therapy of melanoma

Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA

Progress in targeted therapy of melanoma ( Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA )

Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study

Prof Dirk Schadendorf - University of Duisburg-Essen, Essen, Germany

Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study ( Prof Dirk Schadendorf - University of Duisburg-Essen, Essen, Germany )

Management of acute metastatic melanoma

Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK

Management of acute metastatic melanoma ( Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK )

How should we handle talimogene laherparepvec (T-VEC)?

Prof Axel Hauschild - University of Kiel, Kiel, Germany

How should we handle talimogene laherparepvec (T-VEC)? ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )

Combining immunotherapy with stereotactic body radiotherapy

Dr James Welsh - MD Anderson Cancer Center, Houston, USA

Combining immunotherapy with stereotactic body radiotherapy ( Dr James Welsh - MD Anderson Cancer Center, Houston, USA )

Systemic immunotherapy and radiotherapy combination shows promise in advanced...

Dr Susan Hiniker - Stanford University, Stanford, USA

Systemic immunotherapy and radiotherapy combination shows promise in advanced skin cancer ( Dr Susan Hiniker - Stanford University, Stanford, USA )

Is 3D-conformational or intensity-modulated radiation therapy better for NSCLC?

Dr Stephen Chun - MD Anderson Cancer Centre, Houston, USA

Is 3D-conformational or intensity-modulated radiation therapy better for NSCLC? ( Dr Stephen Chun - MD Anderson Cancer Centre, Houston, USA )

More from ecancer